CHF10067 intermediate dose ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
85特発性間質性肺炎1

85. 特発性間質性肺炎


臨床試験数 : 627 薬物数 : 443 - (DrugBank : 120) / 標的遺伝子数 : 99 - 標的パスウェイ数 : 212
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05513950
(ClinicalTrials.gov)
January 25, 202317/8/2022A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibody (mAb) in Patients With IPFA Phase Ib, Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of an Intravenous Monoclonal Antibody (mAB) After Single Ascending Doses in Subjects Affected by Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisBiological: CHF10067 starting dose;Biological: CHF10067 intermediate dose;Biological: CHF10067 high dose;Drug: PlaceboChiesi Farmaceutici S.p.A.NULLRecruiting40 Years80 YearsAll24Phase 1United Kingdom